Celyad Oncology S.A.

CYAD · NASDAQ
Analyze with AI
12/31/2024
6/30/2024
12/31/2023
6/30/2023
Operating Activities
Net Income-$3-$5-$4
Dep. & Amort.$0$0$0
Deferred Tax$0$0-$1
Stock-Based Comp.$0$0$0
Change in WC$0$2-$4
Other Non-Cash-$0-$5-$1
Operating Cash Flow-$3-$7-$8
Investing Activities
PP&E Inv.$0-$1-$0
Net Acquisitions$0$0$1
Inv. Purchases$0$0$0
Inv. Sales/Matur.$0$0$0
Other Inv. Act.-$0$0$1
Investing Cash Flow-$0-$1$1
Financing Activities
Debt Repay.-$0$0-$0
Stock Issued$0$9$0
Stock Repurch.$0$0-$0
Dividends Paid$0$0$0
Other Fin. Act.$2$9$0
Financing Cash Flow$2$9-$0
Forex Effect$0$0-$0
Net Chg. in Cash$6$2-$7
Supplemental Information
Beg. Cash$0$5$12
End Cash$6$7$5
Free Cash Flow-$3-$7-$9
Celyad Oncology S.A. (CYAD) Financial Statements & Key Stats | AlphaPilot